Protagonist Therapeutics, Inc.

NasdaqGM:PTGX Stock Report

Market Cap: US$8.9b

Protagonist Therapeutics Management

Management criteria checks 2/4

Protagonist Therapeutics' CEO is Dinesh Patel, appointed in Dec 2008, has a tenure of 17.58 years. total yearly compensation is $12.87M, comprised of 5.6% salary and 94.4% bonuses, including company stock and options. directly owns 0.45% of the company’s shares, worth $39.56M. The average tenure of the management team and the board of directors is 5.5 years and 11.5 years respectively.

Key information

Dinesh Patel

Chief executive officer

US$12.9m

Total compensation

CEO salary percentage5.56%
CEO tenure17.6yrs
CEO ownership0.4%
Management average tenure5.5yrs
Board average tenure11.5yrs

Recent management updates

Recent updates

Seeking Alpha • Jun 13

Protagonist Therapeutics: A Royalty-Driven Biotech With Two Shots On Goal

Summary Protagonist Therapeutics (PTGX) has transitioned from binary clinical risk to execution risk, leveraging major pharma partners for commercialization without heavy infrastructure costs. ICOTYDE's FDA approval and rusfertide's Priority Review position PTGX for milestone payments, high-margin royalties, and a capital-light revenue model. PTGX maintains a strong balance sheet with $620M+ cash, a funding runway through 2028, and episodic profitability, reducing financing risk. Despite a premium valuation, PTGX offers a compelling bullish setup for investors comfortable with regulatory and launch risks, underpinned by a validated peptide platform. Read the full article on Seeking Alpha
Analysis Article • May 15

This Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This Year

Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) shareholders will have a reason to smile today, with the analysts making...
Analysis Article • May 08

Protagonist Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) last week reported its latest first-quarter results, which makes it a...
Analysis Article • Oct 11

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) 51% Price Boost Is Out Of Tune With Revenues

Despite an already strong run, Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ) shares have been powering on, with a gain...
Seeking Alpha • Mar 11

Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It

Summary Protagonist Therapeutics, Inc. achieved primary endpoint in a phase 3 VERIFY study using rusfertide in polycythemia vera and the phase 2b ANTHEM-UC study using icotrokinra in ulcerative colitis. Icotrokinra, a first-in-class IL-23 receptor agonist, shows promise in treating ulcerative colitis and plaque psoriasis, potentially shifting treatment paradigms in both of these indications. Financially stable with $559.2 million in cash and recent milestone payments, Protagonist can fund operations through 2028, reducing financial risk. Future PTGX prospects include expanding icotrokinra's use to Crohn's Disease and initiating phase 1 study for PN-881, targeting immune-mediated disorders like hidradenitis suppurativa. Read the full article on Seeking Alpha
Seeking Alpha • Jan 13

Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck

Summary Positive results achieved from both ICONIC studies using JNJ-2113 for the treatment of patients with moderate-to-severe plaque psoriasis; Superiority study is data expected in Q2 of 2025. Topline results from the phase 3 VERIFY study, using rusfertide for the treatment of patients with polycythemia vera, expected in Q1 of 2025. The global Polycythemia vera market size is expected to grow to $2.03 billion by 2032. The company had $583.3 million in cash as of September 30th of 2024; Enough cash to fund its operations until the end of 2027. Read the full article on Seeking Alpha
Seeking Alpha • Oct 16

The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey

Summary Today, we circle back to the clinical stage of biopharma Protagonist Therapeutics, Inc., whose stock has tripled over the past year. The company has two late-stage drug candidates that are partnered with Takeda and Johnson & Johnson, respectively. If pivotal trials turn out to be successful, both drugs could be approved in 2026. Still more upside in this rally? An updated analysis of Protagonist Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Feb 25

Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise

Summary Protagonist Therapeutics' stock has experienced significant volatility over the past three years, with multiple setbacks and recoveries. The company's lead drug candidate, Rusfertide, indicated for polycythemia vera, faced a clinical hold from the FDA but had the hold removed in October 2021 and now looks approvable. Protagonist's joint plaque psoriasis candidate, JNJ-2113, showed positive results in a Phase 2 study, leading to a stock price increase. Both of Protagonist's lead candidates make a case for a commercial approval - although not for 2 more years at least, and there are risks, and hurdles still to be overcome. 2 Phase 3 studies must still be completed. The recently signed deal with Takeda to co-commercialise Rusfertide is a significant boost for Protagonist and has driven its market cap valuation to $1.64bn - I think that is an accurate reflection for its value for now, but may look to buy on any dips. Read the full article on Seeking Alpha
Seeking Alpha • Jun 08

Protagonist: Too Many Red Flags

Protagonist has recently faced a number of mishaps. These make the stock risky. They have a good deal of cash for now.
Seeking Alpha • Feb 01

Protagonist Is Still Being Undervalued Like There's Real Risk

Protagonist Therapeutics is currently working to tackle some serious issues with an underserved form of blood cancer. A recent cancer scare sent shockwaves through the company's valuation, and it has been almost entirely resolved. The current valuation is still a deep discount from the highs prior to the dip.

CEO Compensation Analysis

How has Dinesh Patel's remuneration changed compared to Protagonist Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$115m

Dec 31 2025US$13mUS$716k

-US$130m

Sep 30 2025n/an/a

US$46m

Jun 30 2025n/an/a

US$52m

Mar 31 2025n/an/a

US$56m

Dec 31 2024US$9mUS$681k

US$275m

Sep 30 2024n/an/a

US$171m

Jun 30 2024n/an/a

US$170m

Mar 31 2024n/an/a

US$162m

Dec 31 2023US$7mUS$655k

-US$79m

Sep 30 2023n/an/a

-US$140m

Jun 30 2023n/an/a

-US$138m

Mar 31 2023n/an/a

-US$140m

Dec 31 2022US$6mUS$630k

-US$127m

Sep 30 2022n/an/a

-US$130m

Jun 30 2022n/an/a

-US$133m

Mar 31 2022n/an/a

-US$122m

Dec 31 2021US$6mUS$600k

-US$126m

Sep 30 2021n/an/a

-US$108m

Jun 30 2021n/an/a

-US$81m

Mar 31 2021n/an/a

-US$70m

Dec 31 2020US$2mUS$565k

-US$66m

Sep 30 2020n/an/a

-US$65m

Jun 30 2020n/an/a

-US$73m

Mar 31 2020n/an/a

-US$83m

Dec 31 2019US$2mUS$545k

-US$77m

Compensation vs Market: Dinesh's total compensation ($USD12.87M) is above average for companies of similar size in the US market ($USD8.38M).

Compensation vs Earnings: Dinesh's compensation has increased whilst the company is unprofitable.

CEO

Dinesh Patel (69 yo)

17.6yrs
Tenure
US$12,871,506
Compensation

Dr. Dinesh V. Patel, Ph D., has been the Chief Executive Officer, President and Director at Protagonist Therapeutics, Inc. since December 2008 and serves as its Secretary. He serves as Additional Non-Execu...

Leadership Team

NamePositionTenureCompensationOwnership
Dinesh Patel
CEO, President17.6yrsUS$12.87m0.45%
$ 39.6m
Asif Ali
Executive VP & CFO4.3yrsUS$3.26m0.0040%
$ 353.2k
Arturo Molina
Chief Medical Officer3.7yrsUS$4.10m0.021%
$ 1.9m
Venkat Thalladi
EVP & Chief Technical Officerless than a yearno datano data
Newman Yeilding
Executive VP1.9yrsno datano data
Matthew Gosling
Executive VP and Chief Legal & Business Officer5.8yrsno datano data
Carena Spivey
Executive VP & Chief Human Resources Officer5.5yrsno datano data
Ashok Bhandari
EVP & Chief Discovery Officer5.5yrsno datano data
Carter King
Executive Vice President of Business Development5.3yrsno datano data
Abha Bommireddi
Executive VP & Chief of Staff5.5yrsno datano data
Samuel Saks
Clinical Development Advisor5.5yrsno datano data
5.5yrs
Average Tenure
62yo
Average Age

Experienced Management: PTGX's management team is seasoned and experienced (5.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Dinesh Patel
CEO, President17.6yrsUS$12.87m0.45%
$ 39.6m
Harlan Weisman
Clinical Advisor11.5yrsno datano data
Lewis Williams
Independent Director9.1yrsUS$431.82k0.0080%
$ 706.4k
Chaitan Khosla
Chairman of Scientific Advisory Board11.5yrsUS$188.07kno data
Harold Selick
Independent Chairman17.4yrsUS$428.07k0.090%
$ 8.0m
William Waddill
Independent Director10yrsUS$431.82k0.0080%
$ 706.4k
Charles Craik
Scientific Advisorno datano datano data
Mark Gallop
Scientific Advisorno datano datano data
Wayne Lencer
Clinical Advisorno datano datano data
Aida Habtezion
Clinical Advisorno datano datano data
Ellen Scherl
Clinical Advisorno datano datano data
Bryan Giraudo
Independent Director8.2yrsUS$431.82k0.016%
$ 1.4m
11.5yrs
Average Tenure
69yo
Average Age

Experienced Board: PTGX's board of directors are seasoned and experienced ( 11.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/10 23:01
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Protagonist Therapeutics, Inc. is covered by 19 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBarclays
Evan SeigermanBMO Capital Markets Equity Research
Timothy ChiangCapital One Securities, Inc.